Thesis
SELLAS pivots on two AML bets: GPS Phase 3 REGAL final analysis and SLS009 first-line trial define whether either program reaches approval
GPS is a peptide cancer vaccine in maintenance AML, with a Phase 3 REGAL trial at 78 of 80 pre-specified events and final analysis imminent. The thesis resolves on whether GPS demonstrates a statistically significant overall survival benefit in the REGAL final analysis. If GPS fails, the company depends entirely on SLS009 Phase 2 first-line data, where venetoclax-based combinations including approved ven-aza already dominate newly diagnosed AML.
Focus
GPS Phase 3 REGAL Trial Final Analysis
2025
Bull
A positive final analysis showing statistically significant overall survival benefit for GPS in AML would validate the lead program and position SELLAS to file for regulatory approval, potentially establishing GPS as the first WT1-targeting cancer vaccine in a hematologic malignancy. This would materially de-risk the company's pipeline narrative and likely drive a substantial re-rating, given GPS has been the central pillar of the investment thesis.
Bear
Failure to achieve statistical significance on OS — the primary endpoint — would effectively terminate GPS as a commercial prospect, stripping the company of its lead asset and leaving the thesis entirely dependent on the earlier-stage SLS009 program. The most likely failure modes include insufficient separation in the survival curves, dilution of the treatment effect from crossover or subsequent therapies, or an underpowered subgroup effect that does not generalize to the overall population.
Unlock the full thesis for SLS.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.